title: Re: Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-Blind Multicentre Phase 3B Study (BESIDE).
authors.forename: Alan J
authors.initials: AJ
authors.lastname: Wein
mesh_terms: D000083:Acetanilides; D004311:Double-Blind Method; D006801:Humans; D000069464:Solifenacin Succinate; D013844:Thiazoles; D053201:Urinary Bladder, Overactive
chemical_list: D000083:Acetanilides; D013844:Thiazoles; D000069464:Solifenacin Succinate; C520025:mirabegron